Differential Diagnosis of Atrophy and Lipodystrophy

Introduction

Cutaneous atrophy refers to thinning of one or more layers of the skin, resulting in visible or palpable changes. Lipodystrophy specifically refers to abnormalities in the distribution or amount of subcutaneous adipose tissue—either localized or generalized, and either loss (lipoatrophy) or accumulation (lipohypertrophy). Recognition of these changes aids in diagnosing underlying conditions ranging from localized steroid use to systemic autoimmune disease or metabolic syndromes.

---

25.1 Anatomical Layers and Types of Atrophy

Understanding which layer is affected guides the differential:

[!NOTE] The term "atrophy" in dermatology usually refers to epidermal/dermal thinning. "Lipoatrophy" specifically refers to loss of subcutaneous fat.

---

25.2 Causes of Epidermal and Dermal Atrophy

25.2.1 Physiologic Aging (Senile Atrophy)

• Mechanism: Age-related decline in collagen synthesis, elastic fiber degeneration, and reduced subcutaneous fat.
• Clinical Features:
  • Generalized skin thinning, especially on sun-exposed areas.
  • Easy bruising (Senile purpura) on dorsal forearms and hands.
  • Laxity, fine wrinkling.
• Management: Sun protection, Emollients. Cosmetic treatments (retinoids, fillers) for aesthetics.

25.2.2 Topical Corticosteroid-Induced Atrophy

• Mechanism: Corticosteroids inhibit collagen and glycosaminoglycan synthesis, suppress fibroblast activity.
• Risk Factors:
  • High-potency steroids (Clobetasol, Betamethasone dipropionate).
  • Prolonged use (>2-4 weeks on face, >6-12 weeks on body).
  • Occlusion.
  • Thin skin areas (Face, Flexures, Genitals).
• Clinical Features:
  • Skin Atrophy: Thin, shiny, translucent skin (vessels visible).
  • Striae (Stretch Marks): Linear atrophic bands (initially red/purple, later white).
  • Telangiectasias.
  • Easy Bruising.
  • Perioral dermatitis (rebound after face use).
• Reversibility: Partially reversible if stopped early. Striae are permanent.

25.2.3 Lichen Sclerosus (LS)

• Definition: Chronic inflammatory dermatosis characterized by white, atrophic plaques.
• Demographics: Bimodal (prepubertal girls, postmenopausal women). Rare in men.
• Distribution: Anogenital (most common site), Extragenital.
• Clinical Features:
  • "Porcelain white" atrophic plaques.
  • "Cigarette paper" wrinkling (epidermal atrophy).
  • Fissures, Erosions (especially with scratching).
  • Architectural distortion: Labial fusion, Phimosis (in males).
  • Pruritus (often severe).
• Dermoscopy: White structureless areas, Comedo-like openings (follicular plugs), Hemorrhagic spots.
• Histology: Hyperkeratosis, Atrophic epidermis, Homogenization of upper dermis (pale, hyalinized collagen), Band-like lymphocytic infiltrate.
• Malignancy Risk: Increased risk of vulvar/penile SCC (~5%). Long-term surveillance.
• Treatment: Potent topical steroids (Clobetasol). Long-term maintenance.

25.2.4 Morphea (Localized Scleroderma)

• Definition: Localized fibrosis of the skin without systemic involvement.
• Clinical Phases:
  • Early (Inflammatory): Erythematous or violaceous border ("Lilac ring").
  • Established: Ivory-white, waxy, indurated center. Bound-down skin.
  • Late: Hyperpigmentation or hypopigmentation, ATROPHY.
• Variants: Plaque, Linear (En coup de sabre), Generalized, Deep, Pansclerotic.
• Prognosis: Usually self-limited (3-5 years). Does NOT progress to systemic sclerosis.

25.2.5 Lupus Erythematosus (Discoid LE)

• Clinical Features:
  • Well-demarcated, scaly plaques with central atrophy and scarring.
  • Follicular plugging (keratotic spines).
  • Peripheral hyperpigmentation with central hypopigmentation.
  • Scarring alopecia on scalp.
• Dermoscopy: Follicular plugs, White scarring, Perifollicular scale.

25.2.6 Radiodermatitis (Radiation Dermatitis)

• Timing: Develops months to years after radiation therapy.
• Clinical Features:
  • Located within radiation port.
  • Atrophy, Telangiectasias, Poikiloderma (hyper/hypopigmentation, atrophy, telangiectasia).
  • Skin fragility.
• Malignancy Risk: Increased risk of SCC, BCC within radiation field.

25.2.7 Necrobiosis Lipoidica (NL)

• Definition: Chronic granulomatous dermatosis, strongly associated with diabetes.
• Distribution: Pretibial (shins) in >90%.
• Clinical Features:
  • Well-demarcated, shiny, yellow-brown plaques.
  • Central atrophy (skin so thin that underlying vessels are visible).
  • Telangiectasias.
  • Peripheral violaceous or red-brown border.
  • May ulcerate (poor healing).
• Histology: Palisading granulomas with necrobiotic collagen (layered "layer cake" pattern).
• Association: ~65% have diabetes (DM), but only ~0.3% of diabetics develop NL.

25.2.8 Striae (Stretch Marks)

• Mechanism: Rapid stretching of skin → Disruption of dermal collagen and elastic fibers.
• Causes:
  • Pregnancy.
  • Rapid weight gain/Growth spurts (adolescence).
  • Cushing syndrome (spontaneous or iatrogenic).
  • Topical/Systemic corticosteroids.
• Clinical Features:
  • Early: Red-purple (striae rubrae).
  • Late: White, atrophic (striae albae).
• Distribution: Abdomen, Breasts, Hips, Thighs, Axillae.

---

25.3 Causes of Lipoatrophy (Fat Loss)

25.3.1 Localized Lipoatrophy

Injection-Site Lipoatrophy

• Mechanism: Local fat necrosis due to injected substances.
• Causes:
  • Insulin: Older preparations more commonly; improved with newer analogs. Localized fat loss at injection sites.
  • Corticosteroid Injections: Localized fat atrophy at injection site.
• Clinical Features: Circumscribed depression at injection site.
• Prevention: Rotate injection sites.

Post-Inflammatory Lipoatrophy

• After trauma, pressure (e.g., from tight clothing), panniculitis, or localized inflammation.

Lupus Profundus (Lupus Panniculitis)

• Definition: Panniculitis associated with Lupus Erythematosus.
• Clinical Features:
  • Deep, firm, subcutaneous nodules → Heal with localized lipoatrophy (depressed scars).
  • May have overlying DLE lesions.
• Distribution: Face, Upper arms, Buttocks, Thighs.

25.3.2 Generalized and Partial Lipodystrophy

HIV-Associated Lipodystrophy

• Setting: HIV patients on HAART (especially older regimens: Stavudine, Didanosine, Protease Inhibitors).
• Clinical Features:
  • Peripheral Lipoatrophy: Fat loss from face (buccal fat pad → sunken cheeks), Limbs, Buttocks.
  • Central Lipohypertrophy: Accumulation of fat in abdomen ("Protease paunch"), Dorsocervical ("Buffalo hump"), Breasts.
  • Metabolic consequences: Insulin resistance, Dyslipidemia.
• Management: Switch to lipodystrophy-sparing regimens. Facial fillers for cosmetic restoration.

Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome)

• Clinical Features:
  • Cephalocaudal fat loss: Starts from face and upper body, progresses downward.
  • Legs typically SPARED (may even have excess fat).
• Associations:
  • C3 Nephritic Factor (autoantibody stabilizing C3 convertase) in ~80%.
  • Membranoproliferative glomerulonephritis (MPGN).
• Demographics: Predominantly young women. May follow viral illness.

Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome)

• Inheritance: Autosomal Recessive. Genes: AGPAT2, BSCL2.
• Clinical Features:
  • Birth: Near-total absence of subcutaneous and metabolic fat.
  • Muscular appearance (due to visible musculature without fat cover).
  • Severe metabolic consequences: Marked insulin resistance, Acanthosis Nigricans, Diabetes, Hypertriglyceridemia, Hepatomegaly (fatty liver).
  • Accelerated growth, advanced bone age.
• Prognosis: Multi-organ complications. Requires metabolic management. Metreleptin therapy.

---

25.4 Diagnostic Algorithm

Loading diagram...

---

25.5 Summary Comparison Table

---

25.6 Clinical Pearls

1. White, atrophic anogenital plaque → Lichen sclerosus. Potent topical steroids. Monitor for SCC.
2. Atrophy + Striae + Telangiectasias at same site → Topical steroid overuse. Discontinue, taper.
3. Yellow atrophic plaque on shin + Diabetic → Necrobiosis lipoidica.
4. Face + Limb fat loss + HIV + HAART → HIV lipodystrophy. Consider regimen change.
5. Cephalocaudal fat loss + MPGN → Barraquer-Simons syndrome. Check C3 nephritic factor.
6. Generalized fat loss from birth + Acanthosis nigricans → Congenital lipodystrophy. Metreleptin therapy.
7. Deep nodule → Depression scar → Lupus profundus.